Not independent
Tenure on this board
7.0 yrs
Meeting calendar
MAZE · Annual meeting · Monday, June 8, 2026
Maze Therapeutics Inc
2 nominees · 2 ballot items.
Vote to elect two Class I directors (Jason Coloma, Ph.D. and Neil Kumar, Ph.D.) and to ratify Ernst & Young LLP as the company’s independent registered public accounting firm for 2026.
Market cap
$1.5B
1Y TSR
+86.1%
Board grade
C
Record date
Apr 13, 2026
Filing
DEF 14A
Meeting concluded · Jun 8, 2026
Follow how the vote landed and what changed on Maze Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Class I Directors
ManagementBoard: FORElect Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as Class I directors to serve three-year terms expiring at the 2029 annual meeting.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Ernst & Young LLP as Maze Therapeutics’ independent registered public accounting firm for the year ending December 31, 2026.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
0.3 yrs
Also a director at
Bridgebio Pharma Inc (BBIO)Bridgebio Oncology Therapeutics Inc (BBOT)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 8.3% | 4,567,274 | $136M |
| 2 | TRV GP IV, LLC | 8.1% | 4,473,958 | $134M |
| 3 | ARCH Venture Management, LLC | 7.4% | 4,120,053 | $123M |
| 4 | Deep Track Capital, LP | 6.3% | 3,477,562 | $104M |
| 5 | JANUS HENDERSON GROUP PLC | 5.2% | 2,858,876 | $85M |
| 6 | Paradigm Biocapital Advisors LP | 5.0% | 2,744,399 | $82M |
| 7 | a16z Capital Management, L.L.C. | 3.1% | 1,702,225 | $51M |
| 8 | Venrock Adviser, LLC | 2.9% | 1,602,034 | $48M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 2.6% | 1,435,656 | $43M |
| 10 | Alphabet Inc. | 2.5% | 1,388,583 | $41M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Maze Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.6B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.6B
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$712M
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Reference
Frequently asked questions
- When is the Maze Therapeutics Inc 2026 annual meeting?
- Maze Therapeutics Inc (MAZE) holds its 2026 annual shareholder meeting on Monday, June 8, 2026.
- What is the record date for the Maze Therapeutics Inc 2026 meeting?
- The record date for the Maze Therapeutics Inc 2026 meeting is Monday, April 13, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Maze Therapeutics Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Maze Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Maze Therapeutics Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Maze Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.